Compare · BSX vs NPCE
BSX vs NPCE
Side-by-side comparison of Boston Scientific Corporation (BSX) and Neuropace Inc. (NPCE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and NPCE operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $60.90B, about 301.8x NPCE ($201.8M).
- Over the past year, BSX is down 39.2% and NPCE is up 44.9% - NPCE leads by 84.2 points.
- NPCE has been more active in the news (3 items in the past 4 weeks vs 2 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 15 for NPCE).
- Company
- Boston Scientific Corporation
- Neuropace Inc.
- Price
- $62.06-5.52%
- $16.84-0.09%
- Market cap
- $60.90B
- $201.8M
- 1M return
- -11.05%
- +25.26%
- 1Y return
- -39.23%
- +44.94%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 2
- 3
- Recent ratings
- 25
- 15
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Neuropace Inc.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Latest BSX
- Boston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Boston Scientific announces results for first quarter 2026
- SEC Form EFFECT filed by Boston Scientific Corporation
- SEC Form 424B3 filed by Boston Scientific Corporation
- Boston Scientific downgraded by Raymond James with a new price target
- Boston Scientific announces conference call discussing first quarter 2026 results
- Amendment: SEC Form S-4/A filed by Boston Scientific Corporation
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
- HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism
Latest NPCE
- SEC Form DEFA14A filed by Neuropace Inc.
- SEC Form DEF 14A filed by Neuropace Inc.
- NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
- SEC Form 4 filed by Morrell Martha
- SEC Form 4 filed by Geiger Uri
- SEC Form 4 filed by Lacob Joseph
- SEC Form 4 filed by Kumar Rakhi
- SEC Form 4 filed by Fischer Frank M
- NeuroPace to Present at the Leerink Global Healthcare Conference
- CHIEF MEDICAL OFFICER Morrell Martha sold $399,250 worth of shares (25,000 units at $15.97) and covered exercise/tax liability with 1,340 shares, decreasing direct ownership by 35% to 48,624 units (SEC Form 4)